HEPA insider trading
OTC Markets OTCQB HealthcareHepion Pharmaceuticals, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.
About Hepion Pharmaceuticals, Inc.
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hepatocellular carcinoma (HCC), metabolic liver diseases, and chronic liver diseases in the United States. It developed Rencofilstat, a therapeutic drug candidate that binds and inhibits the function of a specific class of isomerase enzymes called cyclophilins that regulates protein folding, as well as preclinical experiments of Rencofilstat reflects decreased liver fibrosis; liver inflammation; liver tumor burden; and titers of HBV, HCV, and HDV. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Morristown, New Jersey.
Company website: hepionpharma.com
HEPA insider activity at a glance
FilingIQ has scored 21 insider transactions for HEPA since Nov 25, 2020. The most recent filing in our index is dated Apr 21, 2026.
Across the full history, 21 open-market purchases
and 0 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on HEPA insider trades is 63.9/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest HEPA Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Top insiders trading HEPA
Frequently asked
- How many insider trades does FilingIQ track for HEPA?
- FilingIQ tracks 21 Form 4 insider transactions for HEPA (Hepion Pharmaceuticals, Inc.), covering filings from Nov 25, 2020 onwards. 5 of those were filed in the last 90 days.
- Are HEPA insiders net buyers or net sellers?
- Across the full Form 4 history for HEPA, 21 transactions (100%) were open-market purchases and 0 (0%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does HEPA insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
- What sector is HEPA in?
- Hepion Pharmaceuticals, Inc. (HEPA) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $1.81M.
Methodology & sources
Every HEPA insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.